NCT04843579

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.

Conditions

• Myeloma Multiple
• Myeloma
• Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Selinexor	Given as 60 mg oral capsule
DRUG	Clarithromycin	Given as 500 mg oral capsule
DRUG	Pomalidomide	Given as 4 mg oral capsule
DRUG	Dexamethasone	Given as 40 mg oral capsule

Timeline

• Start date: 2021-12-29
• Primary completion: 2022-11-30
• Completion: 2022-12-30
• First posted: 2021-04-13
• Last updated: 2023-10-25
• Results posted: 2023-10-25

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study